within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XA03_Oxaliplatin;

model Oxaliplatin
  extends Pharmacolibrary.Drugs.ATC.L.L01XA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01XA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Oxaliplatin is a third-generation platinum-based antineoplastic agent primarily used in combination with fluoropyrimidines for the treatment of metastatic colorectal cancer. It is widely approved and utilized today as a component of regimens such as FOLFOX.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult cancer patients receiving intravenous oxaliplatin. Typical dose 130 mg/m2 over 2 hours.</p><h4>References</h4><ol><li><p>van Haren, F, et al., &amp; Steegers, M (2020). Intravenous lidocaine affects oxaliplatin pharmacokinetics in simultaneous infusion. <i>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</i> 26(8) 1850–1856. DOI:<a href=\"https://doi.org/10.1177/1078155220905011\">10.1177/1078155220905011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32075507/\">https://pubmed.ncbi.nlm.nih.gov/32075507</a></p></li><li><p>Luo, FR, et al., &amp; Chaney, SG (1999). Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. <i>Cancer chemotherapy and pharmacology</i> 44(1) 19–28. DOI:<a href=\"https://doi.org/10.1007/s002800050940\">10.1007/s002800050940</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10367745/\">https://pubmed.ncbi.nlm.nih.gov/10367745</a></p></li><li><p>Rietveld, PCS, et al., &amp; Koolen, SLW (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 176 116820–None. DOI:<a href=\"https://doi.org/10.1016/j.biopha.2024.116820\">10.1016/j.biopha.2024.116820</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38810398/\">https://pubmed.ncbi.nlm.nih.gov/38810398</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Oxaliplatin;
